文献速递糖尿病肥胖与代谢综合征

在DiRECT和DIADEM-I两项2型糖尿病缓解随机临床试验中,通过有意减重引起的血浆蛋白变化预测心脏代谢健康

Prediction of Cardiometabolic Health Through Changes in Plasma Proteins With Intentional Weight Loss in the DiRECT and DIADEM-I Randomized Clinical Trials of Type 2 Diabetes Remission.
PubMed 文献 · Diabetes Care · 2023-01-01

本研究将SomaSignal预测检测应用于DiRECT(干预组n=118,对照组n=144)和DIADEM-I(干预组n=66,对照组n=76)试验的基线和1年样本,评估血浆蛋白变化对心脏代谢结局的预测能力。结果显示,干预组减重分别达10.2 kg和12.1 kg,心脏代谢SomaSignal指标显著改善;减重>10 kg预测心血管风险显著降低,DiRECT为-19.1%(95%CI -33.4至-4.91),DIADEM-I为-33.4%(95%CI -57.3至-9.6)。

要点

  • DiRECT和DIADEM-I干预组平均减重分别为10.2 kg和12.1 kg,对照组分别为1.0 kg和4.0 kg。
  • 肝脏脂肪、糖耐量、体脂百分比、静息能量率、内脏脂肪和心肺适能等SomaSignal指标显著改善(Bonferroni校正P<0.05)。
  • 减重>10 kg预测心血管风险显著降低:DiRECT为-19.1%(95%CI -33.4至-4.91),DIADEM-I为-33.4%(95%CI -57.3至-9.6)。

核心结论

  • 近期起病的2型糖尿病中有意减重可快速诱导基于蛋白的风险模型变化,与广泛的心脏代谢改善一致,包括心肺适能。
  • 减重>10 kg的蛋白变化也预测较低的心血管风险,为相关进行中的试验提供了积极前景。

研究设计与样本

  • 研究应用SomaSignal预测检测(基于适配体蛋白质组学检测约5,000种血浆蛋白测量得出)于DiRECT和DIADEM-I两项随机临床试验的基线和1年样本。
  • DiRECT干预组n=118,对照组n=144;DIADEM-I干预组n=66,对照组n=76。

主要发现

  • DiRECT(英国)和DIADEM-I(卡塔尔)平均(SD)减重分别为10.2(7.4)kg和12.1(9.5)kg,对照组分别为1.0(3.7)kg和4.0(5.4)kg。
  • DiRECT和DIADEM-I的心脏代谢SomaSignal检测结果均显著改善(Bonferroni校正P<0.05),以相对差异(干预减对照)表示分别为:肝脏脂肪(-26.4%,-37.3%)、糖耐量(-36.6%,-37.4%)、体脂百分比(-8.6%,-8.7%)、静息能量率(-8.0%,-5.1%)、内脏脂肪(-34.3%,-26.1%)、心肺适能(9.5%,10.3%)。
  • 心血管风险(用SomaSignal检测测量)在干预组相对对照组也改善,但仅在DiRECT中显著(DiRECT -44.2%,DIADEM-I -9.2%)。
  • 减重>10 kg预测心血管风险显著降低,DiRECT为-19.1%(95%CI -33.4至-4.91),DIADEM-I为-33.4%(95%CI -57.3至-9.6)。
  • DIADEM-I还显示3个月时代谢改善快速出现。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the extent to which changes in plasma proteins, previously predictive of cardiometabolic outcomes, predict changes in two diabetes remission trials. RESEARCH DESIGN AND METHODS: We applied SomaSignal predictive tests (each derived from ∼5,000 plasma protein measurements using aptamer-based proteomics assay) to baseline and 1-year samples of trial intervention (Diabetes Remission Clinical Trial [DiRECT], n = 118, and Diabetes Intervention Accentuating Diet and Enhancing Metabolism [DIADEM-I], n = 66) and control (DiRECT, n = 144, DIADEM-I, n = 76) group participants. RESULTS: Mean (SD) weight loss in DiRECT (U.K.) and DIADEM-I (Qatar) was 10.2 (7.4) kg and 12.1 (9.5) kg, respectively, vs. 1.0 (3.7) kg and 4.0 (5.4) kg in control groups. Cardiometabolic SomaSignal test results showed significant improvement (Bonferroni-adjusted P < 0.05) in DiRECT and DIADEM-I (expressed as relative difference, intervention minus control) as follows, respectively: liver fat (-26.4%, -37.3%), glucose tolerance (-36.6%, -37.4%), body fat percentage (-8.6%, -8.7%), resting energy rate (-8.0%, -5.1%), visceral fat (-34.3%, -26.1%), and cardiorespiratory fitness (9.5%, 10.3%). Cardiovascular risk (measured with SomaSignal tests) also improved in intervention groups relative to control, but this was significant only in DiRECT (DiRECT, -44.2%, and DIADEM-I, -9.2%). However, weight loss >10 kg predicted significant reductions in cardiovascular risk, -19.1% (95% CI -33.4 to -4.91) in DiRECT and -33.4% (95% CI -57.3, -9.6) in DIADEM-I. DIADEM-I also demonstrated rapid emergence of metabolic improvements at 3 months. CONCLUSIONS: Intentional weight loss in recent-onset type 2 diabetes rapidly induces changes in protein-based risk models consistent with widespread cardiometabolic improvements, including cardiorespiratory fitness. Protein changes with greater (>10 kg) weight loss also predicted lower cardiovascular risk, providing a positive outlook for relevant ongoing trials.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Sattar N, Taheri S, Astling DP, et al. Prediction of Cardiometabolic Health Through Changes in Plasma Proteins With Intentional Weight Loss in the DiRECT and DIADEM-I Randomized Clinical Trials of Type 2 Diabetes Remission. Diabetes Care. 2023. PMID: 37756566. doi:10.2337/dc23-0602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。